Cagrilintide vs GLP-3/RT
Two different hormone systems aimed at the same research question — and the reason they are studied together far more often than against each other.
How they actually differ
These are not competing versions of the same idea. GLP-3/RT is an incretin molecule, engineered to hit GIP, GLP-1 and glucagon receptors at once. Cagrilintide works nowhere near those targets: it acts at the calcitonin receptor and the three amylin receptors, which are calcitonin-receptor heterodimers. That is why the published work pairs an amylin analogue with an incretin agonist rather than choosing between them — the pathways are separate. In handling they are close cousins, both acylated with a C20 fatty diacid, both foam if shaken, both refrigerated after mixing. The difference is what failure looks like: GLP-3/RT aggregates at the air–liquid interface, while cagrilintide has amylin’s fibril pathway underneath it, which is what its whole sequence design exists to hold shut.
Cagrilintide — origin
Cagrilintide is an engineered analogue of human amylin (IAPP), the 37-residue hormone co-secreted with insulin from pancreatic beta cells. Its design problem was unusually specific: native amylin is strongly amyloidogenic, readily collapsing from helix into the beta-sheet conformation that seeds fibrils, which is what made a long-acting amylin drug difficult for decades. Cagrilintide carries six substitutions relative to human amylin (14E, 17R, 25P, 28P, 29P, 37P) — roughly 84% sequence homology — plus N-terminal acylation with a C20 fatty diacid through a gamma-glutamate linker.
GLP-3/RT — origin
GLP-3/RT is a rationally engineered single peptide chain designed to activate three receptors at once — GIP, GLP-1, and glucagon. It represents the third generation of incretin design: mono-agonists first, dual agonists such as GLP-2/Tirz second, and triagonists third. Adding glucagon-receptor activity is the conceptual leap, since glucagon signalling contributes energy expenditure rather than only appetite and glycaemic effects.
Cagrilintide research themes
Cagrilintide binds the calcitonin receptor and all three amylin receptors (AMY1, AMY2, AMY3), which is why the literature sometimes classes it as a dual amylin and calcitonin receptor agonist.
A worked example of engineering a fibril-prone hormone into a stable long-acting analogue — salt-bridge helix stabilisation plus beta-sheet-breaking prolines.
The C20 diacid extends the half-life from minutes, for the short-acting analogue pramlintide, to roughly a week.
The most-studied context: co-administration with semaglutide, investigated in the REDEFINE trial programme.
GLP-3/RT research themes
The defining feature: simultaneous GIP, GLP-1, and glucagon receptor activity from one chain.
Glucagon-receptor activity is studied for its contribution to energy expenditure, distinguishing triagonists from dual agonists.
Investigated in metabolic research models for effects on glucose homeostasis.
A major focus of the preclinical literature on this compound class.
Cagrilintide handling
- Never shake. Swirl gently and allow the cake to dissolve in its own time.
- Do not freeze reconstituted solution.
- Add diluent down the vial wall rather than directly onto the cake.
- Treat visible particulate or a settling precipitate as a rejected vial — for an amylin analogue this is the observable end of the fibrillation pathway, not a cosmetic issue.
GLP-3/RT handling
- Never shake. Foam on a lipidated peptide solution is denatured material at the air–liquid interface, not a cosmetic issue.
- Introduce diluent slowly down the vial wall and allow the cake to dissolve without agitation, which may take several minutes.
- Do not freeze reconstituted solution — aggregation from freeze–thaw is irreversible.
- Faint opalescence at high concentration is expected; visible particulate is not.
Both third-party tested
Every Popular Peptides batch of Cagrilintide and GLP-3/RT is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
Cagrilintide reference
Related comparisons
Cagrilintide and GLP-3/RT are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.